GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Swedish Orphan Biovitrum AB (MEX:SOBI N) » Definitions » E10

Swedish Orphan Biovitrum AB (MEX:SOBI N) E10 : MXN0.00 (As of Jun. 2025)


View and export this data going back to 2020. Start your Free Trial

What is Swedish Orphan Biovitrum AB E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Swedish Orphan Biovitrum AB's adjusted earnings per share data for the three months ended in Jun. 2025 was MXN3.609. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is MXN0.00 for the trailing ten years ended in Jun. 2025.

During the past 12 months, Swedish Orphan Biovitrum AB's average E10 Growth Rate was 14.70% per year. During the past 3 years, the average E10 Growth Rate was 22.50% per year. During the past 5 years, the average E10 Growth Rate was 27.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Swedish Orphan Biovitrum AB was 81.70% per year. The lowest was 22.50% per year. And the median was 34.80% per year.

As of today (2025-07-18), Swedish Orphan Biovitrum AB's current stock price is MXN523.55284. Swedish Orphan Biovitrum AB's E10 for the quarter that ended in Jun. 2025 was MXN0.00. Swedish Orphan Biovitrum AB's Shiller PE Ratio of today is .

During the past 13 years, the highest Shiller PE Ratio of Swedish Orphan Biovitrum AB was 545.59. The lowest was 28.96. And the median was 44.21.


Swedish Orphan Biovitrum AB E10 Historical Data

The historical data trend for Swedish Orphan Biovitrum AB's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Swedish Orphan Biovitrum AB E10 Chart

Swedish Orphan Biovitrum AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 13.65 15.50 14.04 13.97

Swedish Orphan Biovitrum AB Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.12 12.84 13.97 15.81 -

Competitive Comparison of Swedish Orphan Biovitrum AB's E10

For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Swedish Orphan Biovitrum AB's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Swedish Orphan Biovitrum AB's Shiller PE Ratio falls into.


;
;

Swedish Orphan Biovitrum AB E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Swedish Orphan Biovitrum AB's adjusted earnings per share data for the three months ended in Jun. 2025 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Jun. 2025 (Change)*Current CPI (Jun. 2025)
=3.609/132.8245*132.8245
=3.609

Current CPI (Jun. 2025) = 132.8245.

Swedish Orphan Biovitrum AB Quarterly Data

per share eps CPI Adj_EPS
201509 0.039 100.228 0.052
201512 -0.097 100.276 -0.128
201603 2.208 100.751 2.911
201606 2.446 101.019 3.216
201609 1.082 101.138 1.421
201612 0.599 102.022 0.780
201703 1.513 102.022 1.970
201706 1.950 102.752 2.521
201709 2.597 103.279 3.340
201712 2.950 103.793 3.775
201803 4.001 103.962 5.112
201806 5.395 104.875 6.833
201809 4.597 105.679 5.778
201812 4.548 105.912 5.704
201903 6.221 105.886 7.804
201906 3.296 106.742 4.101
201909 3.554 107.214 4.403
201912 8.785 107.766 10.828
202003 9.055 106.563 11.287
202006 2.250 107.498 2.780
202009 2.216 107.635 2.735
202012 11.428 108.296 14.016
202103 5.325 108.360 6.527
202106 2.038 108.928 2.485
202109 3.613 110.338 4.349
202112 9.011 112.486 10.640
202203 3.639 114.825 4.209
202206 1.647 118.384 1.848
202209 2.618 122.296 2.843
202212 8.360 126.365 8.787
202303 5.850 127.042 6.116
202306 1.130 129.407 1.160
202309 0.471 130.224 0.480
202312 4.948 131.912 4.982
202403 3.714 132.205 3.731
202406 1.136 132.716 1.137
202409 8.123 132.304 8.155
202412 7.632 132.987 7.623
202503 5.088 132.825 5.088
202506 3.609 132.825 3.609

Add all the adjusted EPS together and divide 10 will get our e10.


Swedish Orphan Biovitrum AB  (MEX:SOBI N) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

During the past 13 years, the highest Shiller P/E Ratio of Swedish Orphan Biovitrum AB was 545.59. The lowest was 28.96. And the median was 44.21.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Swedish Orphan Biovitrum AB E10 Related Terms

Thank you for viewing the detailed overview of Swedish Orphan Biovitrum AB's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Swedish Orphan Biovitrum AB Business Description

Address
Tomtebodavagen 23 A, Solna, Stockholm, SWE, SE-112 76
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) in 2006 on long-acting hemophilia factor replacement programs. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare-disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).

Swedish Orphan Biovitrum AB Headlines

No Headlines